Tirzepatide

Overview

Tirzepatide is a prescription peptide medication sold under the brand names Mounjaro (for type 2 diabetes) and Zepbound (for weight management). It is approved by the FDA and other regulators and is administered as a once-weekly injection. It belongs to a newer generation of metabolic drugs that has drawn significant attention for its effects on blood sugar and body weight.

What distinguishes tirzepatide is that it is a dual agonist, acting on two gut hormone receptors at once rather than one. This design builds on the established GLP-1 class of medicines but adds a second mechanism, and in clinical trials it has produced some of the largest average weight reductions seen among approved pharmacotherapies.

Because it is an approved, prescribed medicine, tirzepatide is used under medical supervision with defined indications, monitoring, and dosing schedules, a meaningful contrast to the unregulated research peptides also discussed in this encyclopedia.

How it works

Tirzepatide activates the receptors for two incretin hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). Both are naturally released by the gut after eating and help regulate blood sugar and appetite. By stimulating both pathways, tirzepatide engages a broader slice of the body's own metabolic signaling than single-receptor drugs.

Through GLP-1 activity, it enhances insulin secretion when blood glucose is elevated, suppresses excess glucagon, and slows gastric emptying, which contributes to feeling full sooner and longer. The added GIP activity is thought to complement these effects on insulin response and appetite, though the precise contribution of GIP is still an area of active scientific discussion.

The combined result is improved blood sugar control and reduced food intake. These appetite and satiety effects help explain the substantial weight loss observed, since patients tend to eat less while the drug also improves how the body handles glucose.

Clinical evidence

Tirzepatide was studied in two major clinical trial programs. The SURPASS trials evaluated it in people with type 2 diabetes, examining its effects on blood sugar control, and the SURMOUNT trials evaluated it for weight management in people with obesity or overweight. These programs supported its regulatory approvals.

Across these studies, tirzepatide produced strong reductions in HbA1c (a marker of long-term blood sugar) and notable reductions in body weight, with the degree of weight loss being among the largest reported for an approved medication in this class. Trials also commonly compared it against existing treatments, including GLP-1-only therapies.

As with any medicine, the trial results reflect controlled conditions and defined populations. Long-term outcomes, durability of weight loss after stopping, and effects across diverse groups continue to be studied. The evidence base is robust enough to support approval, while ongoing research continues to refine understanding of its broader cardiovascular and metabolic effects.

Dosing & side effects

Tirzepatide is a once-weekly injection that is started at a low dose and increased gradually under medical guidance to improve tolerability. Specific dosing must be determined and supervised by a prescribing clinician, and this encyclopedia does not provide dosing instructions. Self-directed use of unregulated or compounded versions carries added risk.

The most common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, and reduced appetite. These are often most pronounced when starting or increasing the dose and tend to ease over time. Gradual dose escalation is used specifically to limit these effects.

More serious but less common concerns can include pancreatitis, gallbladder problems, and low blood sugar (particularly when combined with other glucose-lowering drugs). The labeling also carries a warning regarding thyroid C-cell tumors based on animal studies. Anyone using tirzepatide should do so under medical supervision, report worrisome symptoms promptly, and discuss their personal risk factors with a clinician.

Legal status

Tirzepatide is an FDA-approved prescription medication and is approved by regulators in many other countries as well. It is legally available only with a valid prescription, under the brand names Mounjaro for type 2 diabetes and Zepbound for weight management, with approved indications defining who it is intended for.

Because demand has been high, a market for compounded and unofficial versions has emerged at various times. These are not the same as the approved branded product and may not carry the same guarantees of purity, dosing accuracy, or oversight. Regulatory agencies have repeatedly cautioned about products sold outside the approved supply chain.

For consumers, the key point is that legitimate tirzepatide is obtained through a licensed prescriber and pharmacy. Products marketed online without a prescription, or sold as research material, fall outside the approved framework and should be regarded with the same caution as any unregulated injectable.

Tirzepatide vs Semaglutide

The two leading weight-loss peptides, compared on the points people ask about most.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. Peer-reviewed study
2. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. Peer-reviewed study
3. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025. Peer-reviewed study
4. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. Peer-reviewed study
5. Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. Peer-reviewed study
6. Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. Peer-reviewed study